March 26 (Reuters) - The U.S. Food and Drug Administration approved Soleno Therapeutics' SLNO.O drug to treat a rare genetic disorder on Wednesday, making it the first treatment available for patients who experience feelings of intense and persistent hunger.
(Reporting by Sneha S K and Bageshri Banerjee in Bengaluru; Editing by Krishna Chandra Eluri and Alan Barona)
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.